𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The incidence of leukemia and related diseases in patients with rheumatoid (ankylosing) spondylitis treated with X-ray therapy

✍ Scribed by Donald H. Silberberg; Lawrence A. Frohman; Ivan F. Duff

Publisher
John Wiley and Sons
Year
1960
Tongue
English
Weight
779 KB
Volume
3
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In a series of 496 rheumatoid spondylitis patients treated with x‐ray, the authors have reported an incidence of leukemia over 17 times greater than expected in a comparable population. No conclusion can be drawn with respect to the exact nature of dose‐response relationship in leukemogenesis. Four of the reported leukemias arose from myeloid reticular elements of the bone marrow; the fifth case is of undetermined origin. Since the chief use of x‐ray therapy under these circumstances is as an analgesic, it would seem unwise to compound the risk of developing leukemia in these patients by its continued use unless all other forms of symptomatic treatment have failed and the patient and the physician mutually accept the possibility of this increased hazard.

📜 SIMILAR VOLUMES

Decreased incidence of anterior uveitis
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept
✍ J. Braun; X. Baraliakos; J. Listing; J. Sieper 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Abstract ## Objective To estimate the incidence of anterior uveitis in patients with ankylosing spondylitis (AS) who underwent anti–tumor necrosis factor (anti‐TNF) therapy, using data from recently performed trials. ## Methods Data from 4 placebo‐controlled studies with anti‐TNF agents in AS

Validation exercise of the Ankylosing Sp
Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics
✍ Stone, Millicent A. ;Inman, Robert D. ;Wright, James G. ;Maetzel, Andreas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## Abstract ## Objectives To define what expert clinicians consider a dramatic response in ankylosing spondylitis (AS) patients treated with biologic therapies based on patient and physician assessments of global disease activity. To compare this expert clinician‐derived criteria to the Ankylosing

Differences in the incidence of flares o
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents
✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co

Preliminary clinical measurement of the
Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis
✍ Yang Zai-Xing; Liang Yan; Wang Hao; Zhu Ye; Li Chang; Zhong Ren-Qian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

## Abstract It has recently been reported that tumor necrosis factor (TNF)‐related apoptosis inducing ligand (TRAIL) plays various roles in such autoimmune diseases as diabetes, multiple sclerosis (MS), and systemic lupus erythematosus (SLE). However, it has still remained unclear whether there is